Efprezimod Alfa (CD24Fc, MK-7110)

CD24Fc · Oncoimmune, Inc., a subsidiary of Merck & Co., Inc.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for Efprezimod Alfa (CD24Fc, MK-7110), covering 2021-06-18 to 2022-06-08. Get the full timeline:

Most recent: Clinical Trial Update: Efprezimod Alfa (CD24Fc, MK-7110) Administration to Decrease Low-Density Lipoprotein (LDL) and Inflammation in Human Immunodeficiency Virus (HIV) Patients (CALIBER) (MK-7110-003) [Phase 2]

See pricing